Concepedia

Axel Haupt

AH

Statistics

Publications

75

Citations

10.2K

H-Index

45

Active since

1996

Affiliations

Eli Lilly (United States)(Current)

University of Tübingen

Velocity Clinical Research (United States)

University Medical Center Groningen

Eli Lilly (Germany)

Axel Haupt is an author at Eli Lilly (United States) specializing in medicine, diabetes mellitus, and pharmacology.

ORCID

Publications per year

1996–2025

75

Publications

75

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías et al. · New England Journal of Medicine · 2023 · 966 citations

, , +17

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Tamer Coşkun, Kyle W. Sloop, Corina Loghin et al. · Molecular Metabolism · 2018 · 822 citations · Full text

, , +17

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Juan P. Frías, Michael A. Nauck, Joanna Van et al. · The Lancet · 2018 · 799 citations

, , +17

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

Rohit Loomba, Mark L. Hartman, Eric Lawitz et al. · New England Journal of Medicine · 2024 · 783 citations

, , +17

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Sean Wharton, Thomas Blevins, Lisa Connery et al. · New England Journal of Medicine · 2023 · 418 citations

, , +17

1–5 of 75